Dapagliflozin (Farxiga, AstraZeneca) is a selective SGLT2 inhibitor approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The possibility that T2D patients might be at increased risk in developing AD has serious societal implications. This is a selective and reversible inhibitor cotransporter 2 sodium-glucose (SGLT2) acting independently of insulin, aiding removal of excess glucose in the body, differently from as what do the rest of antidiabetic drugs. Dapagliflozin is, after the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (TRAJENTA; a-t 2011; 42: 73-4) and the insulin analogue degludec (TRESIBA), the third diabetes drug to either be withdrawn from the market or not even to be launched in the first place, due to their benefit assessment within the framework of the AMNOG (Pharmaceutical Market Restructuring Act). At this time, no PAAT is available for Forxiga. Dapagliflozin, administered from initiation of high-fat feeding, reduced the development of hyperglycaemia; after 24 days, blood glucose was 8.6 ± 0.5 vs. Back in May, the Committee for Medicinal Products for Human Use of the European Medicines Agency published a positive opinion on Forxiga.
Most patients were on multiple medications, including antidiabetic medications and insulin, with 41% to 44% in both studies being treated with insulin or oral agents and about 40% being treated with at least two oral therapies in both studies, Cefalu said. With